• Non-small Cell Lung Cancer: Combination Therapy Doubles Survival Rate

    7 days ago - By Medindia Health

    The immunotherapy drug pembrolizumab, when combined with chemotherapy, doubles survival in patients with non-squamous non-small cell lung cancer when compared to chemotherapy alone.
    Read more ...